boserolimab (MK-5890) / Merck (MSD), Novartis 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
boserolimab (MK-5890) / Merck (MSD), Novartis
MK-5890-003, NCT06829199: A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer

Not yet recruiting
2
100
NA
Pembrolizumab, MK-3475, Keytruda®, SCH 900475, Paclitaxel, Carboplatin, Doxorubicin (hydrochloride), Boserolimab, MK-5890, Epirubicin Hydrochloride, Cyclophosphamide, Capecitabine, Olaparib (if approved/available locally)
Merck Sharp & Dohme LLC
Early Triple Negative Breast Cancer
01/29
03/31
KEYNOTE-B99, NCT04924101 / 2020-005649-17: Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ )

Active, not recruiting
2
120
Europe, Canada, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, SCH 900475, MK-4830, Boserolimab, MK-5890, Lenvatinib, LENVIMA®, KISPLYX®, MK-7902, E7080, Etoposide, Etopophos®, Vepesid®, Toposar®, VP-16, Etoposide phosphate, Cisplatin, Platinol-AQ, Platinol, CDDP, Carboplatin, Paraplatin, Paraplatin NovaPlus, Carboplatin N+ Novaplus, Carboplatin Novaplus, PremierPro Rx Carboplatin
Merck Sharp & Dohme LLC
Small Cell Lung Cancer
07/26
07/26
KEYMAKER-U01C, NCT04165096 / 2020-001629-29: KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/)

Active, not recruiting
2
135
Europe, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, SCH 900475, Boserolimab, MK-5890, MK-4830, diphenhydramine, acetaminophen, MK-0482
Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
02/32
02/32
KEYMAKER-U01A, NCT04165070 / 2020-001626-56: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/)

Hourglass Jan 2022 - Dec 2022 : Of KEYNOTE-01A trial for advanced NSCLC
Recruiting
1/2
450
Europe, US, RoW
Pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®, Carboplatin, PARAPLATIN®, Paclitaxel, ABRAXANE®, Pemetrexed, ALIMTA®, Vibostolimab, MK-7684, Boserolimab, MK-5890, MK-4830, MK-0482, Ifinatamab Deruxtecan (I-DXd), DS-7300a, MK-2400, HER3-DXd, U3-1402, MK-1022
Merck Sharp & Dohme LLC, Daiichi Sankyo
Carcinoma, Non-Small-Cell Lung
02/39
02/39
MK-5890-001, NCT03396445: Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors

Checkmark Presentation of data from trial in combination with Keytruda in solid tumors at SITC 2019
Nov 2019 - Nov 2019: Presentation of data from trial in combination with Keytruda in solid tumors at SITC 2019
Completed
1
184
Europe, US, RoW
Boserolimab, MK-5890, Pembrolizumab, MK-3475, Pemetrexed, ALIMTA®, Carboplatin, PARAPLATIN®, Nab-paclitaxel, ABRAXANE®
Merck Sharp & Dohme LLC
Pharmacokinetics, Solid Tumor, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms
09/24
09/24

Download Options